卡瑞利珠单抗：全球首次获批。
Camrelizumab: First Global Approval.
机构信息
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
出版信息
Drugs. 2019 Aug;79(12):1355-1361. doi: 10.1007/s40265-019-01167-0.
Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. The drug is also being investigated as a treatment for various other malignancies, including B cell lymphoma, oesophageal squamous cell carcinoma, gastric/gastroesophageal junction cancer, hepatocellular carcinoma, nasopharyngeal cancer and non-squamous, non-small cell lung cancer. This article summarizes the milestones in the development of camrelizumab leading to this first approval for classical Hodgkin lymphoma.
卡瑞利珠单抗（艾瑞卡 ® ）是江苏恒瑞医药股份有限公司开发的一种程序性死亡受体 1（PD-1）抑制剂，最近在中国获批用于治疗复发或难治性经典型霍奇金淋巴瘤。该药也在研究用于治疗多种其他恶性肿瘤，包括 B 细胞淋巴瘤、食管鳞状细胞癌、胃/胃食管交界处癌、肝细胞癌、鼻咽癌和非鳞状非小细胞肺癌。本文总结了卡瑞利珠单抗开发过程中的重要里程碑，最终使其获得经典型霍奇金淋巴瘤的首个批准。
Zotero 插件